Grocery business Publix said on Tuesday that its is suspending the administration of the Johnson & Johnson COVID-19 vaccine at all of its pharmacy locations following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA).
The CDC and FDA have issued a joint media statement with additional information about the Johnson & Johnson COVID-19 vaccine.
While a rare side effect, individuals who have received the Johnson & Johnson COVID-19 vaccine should contact their health care provider if they develop a severe headache, abdominal pain, leg pain or shortness of breath within three weeks, according to the CDC and FDA.
However, the customers can visit publix.com/covidvaccine to schedule an appointment for the Moderna COVID-19 vaccine, if currently available in their state.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses